Skip to main content
Premium Trial:

Request an Annual Quote

Physiome Plans for Busy Partnering Season in Q1

SAN FRANCISCO, Jan. 7 - Physiome Sciences plans to strike a number of "partnerships," including potential mergers or acquisitions, during the first quarter, the company said at an international healthcare conference here.


The privately held firm also intends to introduce an updated version of its PathwayPrism modeling technology in the quarter.


Speaking at the 20th annual JPMorgan H&Q Healthcare Conference here on Monday, Mark M. Engelhart, vice president for commercial development at Physiome, said that the first three months of 2002 will see "a number of … partnerships" within the industry, which might include "M and A activity."


He would not specify the nature of the collaborations or with whom they will be struck, but he said that they would be with companies that possess proteomic databases and those that deal with "data structure and data mining."


Engelhart spoke at the meeting, which ends on Thursday, after Jeremy Levin, Physiome's president and CEO and planned speaker, left due to a death in the family.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.